Men Do Better than Women on Cancer Immunotherapies
(MedPage Today) -- Overall survival improvement twice as great, meta-analysis finds
AstraZeneca said on Friday its immunotherapy drug Imfinzi did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on its shares.
AstraZeneca's combination of two immunotherapy drugs did not meet the main goal in a closely watched late-stage study for certain type of stage IV lung cancer, the company said on Friday.
This article highlights the evidence-based data to support systemic treatment options for patients with head and neck squamous cell carcinoma (HNSCC). The discovery of the human papillomavirus epidemic in HNSCC and its favorable prognosis has led to a major focus of research. Patients are stratified into clinical or pathologic risk categories and enrolled in trials comparing standard treatment paradigms with deintensification, in low-risk disease, or to intensification, in intermediate-risk or high-risk disease. Immunotherapy has proven beneficial in second-line palliative therapy and is under investigation in first-line p...
This article provides an overview of the interaction between immune infiltrating cells in the tumor microenvironment, and the immunologic principles related to HNSCC. Current i mmunotherapeutic strategies and emerging results from ongoing clinical trials are presented.
Swiss drugmaker Roche said on Tuesday its Tecentriq medicine will get a speedy review by U.S. regulators in a tough-to-treat form of breast cancer, as it seeks to be the first company to have its immunotherapy win approval in this indication.Reuters Health Information
Extended follow-up from the CheckMate 032 trial showed strong results with three different immunotherapy regimens involving nivolumab and ipilimumab in patients with previously treated metastatic urothelial carcinoma.
Condition: Triple Negative Breast Cancer (TNBC) Interventions: Biological: spartalizumab; Biological: LAG525; Drug: NIR178; Drug: capmatinib; Biological: MCS110; Biological: canakinumab Sponsor: Novartis Pharmaceuticals Not yet recruiting
Condition: Lung Neoplasm Intervention: Sponsors: Wake Forest University Health Sciences; National Cancer Institute (NCI); Lung Cancer Initiative of North Carolina Active, not recruiting
CONCLUSION: The data presented do not justify a change of current treatment paradigms just yet. However, interesting developments can be expected in the coming years, particularly in the field of immunotherapy. PMID: 30421001 [PubMed - as supplied by publisher]
This article aims to describe the plausible mechanisms of ICI related cardiotoxicity as well as strategies for clinicians to recognize and manage cardiotoxicity. As immunotherapy based treatment strategies continue to widen and the population of patients receiving these agents expands, increasing provider awareness of potentially fatal toxicities will continue to be an important issue.